The Resource Hematopoietic stem-cell transplantation in the pediatric population, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center ; investigators, Thomas A. Ratko ... [et al.], (electronic resource)

Hematopoietic stem-cell transplantation in the pediatric population, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center ; investigators, Thomas A. Ratko ... [et al.], (electronic resource)

Label
Hematopoietic stem-cell transplantation in the pediatric population
Title
Hematopoietic stem-cell transplantation in the pediatric population
Statement of responsibility
prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center ; investigators, Thomas A. Ratko ... [et al.]
Contributor
Subject
Language
  • eng
  • eng
Summary
OBJECTIVES: Assess comparative benefits and harms of hematopoietic stem-cell transplantation (HSCT) versus standard therapies or disease natural history in pediatric (age 21 years) patients with malignant solid tumors, inherited metabolic diseases, or autoimmune diseases. DATA SOURCES: MEDLINE(r), Embase, and the Cochrane Database of Systematic Reviews weresearched from January 1995 through August 2011. Additional studies were identified from reference lists and technical experts. REVIEW METHODS: Major data abstraction elements were patient and treatment characteristics, health outcomes (overall survival, remission, neurocognitive development, adverse events), and data analysis. The strength of the body of evidence for each indication was assessed according to the process developed by the Evidence-based Practice Center (EPC) Program of the Agency for Healthcare Research and Quality using four required domains specified in the EPC Methods Guide for Comparative Effectiveness Reviews: risk of bias, consistency, directness, and precision. In cases where there were no head-to-head comparative studies, directness was based on the outcome (e.g., overall survival) rather than on the comparison. For small series or a compilation of case reports in which the prognosis absent HSCT is uniformly fatal (e.g., Wolman's disease), the known natural history was considered an indirect comparator. An optional domain, strength of association (SOA, magnitude of effect) was applied to the body of evidence when there was an apparent benefit or harm, increasing the overall strength beyond what normally may be considered appropriate for such evidence. SOA was deemed not applicable for diseases where there was no clear evidence of benefit or harm with HSCT versus comparators, or if results of individual studies within a body of literature were inconsistent or conflicted. No quantitative scoring method was applied. RESULTS: Among 6,416 records screened, 251 primary studies were included. The strength of evidence for specific indications was graded as high for 2 indications, moderate or low for 19, and insufficient for 39.1. Evidence suggesting a benefit of HSCT for overall survival:1.1. Wolman's disease compared to disease natural history (high strength)1.2. Recurrent/progressive anaplastic astrocytoma compared to conventional therapy (low strength)2. Evidence suggesting a benefit of HSCT for neuromuscular symptoms:1.1. Farber's disease Type 2/3 compared to symptom management and disease natural history (high strength)3. Evidence suggesting a benefit of HSCT for neurocognitive symptoms:1.1. Infantile ceroid lipofuscinosis compared to symptom management or disease natural history (low strength)1.2. Attenuated form of MPS (mucopolysaccharoidosis) II (Hunter's disease) compared to enzyme-replacement therapy (ERT) (low strength)4. Evidence suggesting a benefit of HSCT for neurodevelopmental symptoms:1.1. Attenuated and severe forms of MPS II (Hunter's disease) compared to ERT (both low strength)5. Evidence suggesting no benefit of single HSCT for overall survival:1.1. Metastatic rhabdomyosarcoma compared to conventional therapy (moderate strength)1.2. Extraocular retinoblastoma with central nervous system involvement, high-risk Ewing's sarcoma family of tumors, high-risk relapsed Wilm's tumor compared to conventional therapy (all three low strength)1.3. Niemann-Pick Type A compared to symptom management (low strength)6. Evidence suggesting no benefit of HSCT for neurodevelopmental symptoms:1.1. Gaucher Type III compared to ERT (low strength)1.2. Juvenile form of GM1, juvenile Tay-Sachs compared to symptom management or disease natural history (both low strength)1.3. MPS III (Sanfilippo) compared to symptom management, substrate reduction therapy, or disease natural history (low strength)7. Evidence suggesting no benefit of HSCT for neurocognitive symptoms:1.1. Severe form of MPS II (Hunter's disease) compared to symptom management or disease natural history (low strength)1.2. MPS III (Sanfilippo) compared to symptom management, substrate reduction therapy, or disease natural history (low strength)1.3. Gaucher Type III compared to ERT (moderate strength)8. Evidence suggesting harm of HSCT for overall survival:1.1. Nonanaplastic mixed or unspecified ependymoma compared to conventional therapy (both low strength) CONCLUSIONS: Evidence demonstrating benefit or harm of HSCT versus standard therapies or disease natural history was insufficient for most pediatric indications
Member of
Cataloging source
DNLM
Funding information
Contract No. HHSA 290-2007-10058
Government publication
federal national government publication
Illustrations
illustrations
Index
no index present
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
NLM call number
WH 380
http://library.link/vocab/relatedWorkOrContributorName
  • Ratko, Thomas
  • Effective Health Care Program
  • United States
  • Blue Cross and Blue Shield Association
Series statement
  • Comparative effectiveness review
  • AHRQ publication
Series volume
  • no. 48
  • no. 12-EHC018-EF
http://library.link/vocab/subjectName
  • Hematopoietic Stem Cell Transplantation
  • Neoplasms
  • Metabolic Diseases
  • Autoimmune Diseases
  • Infant
  • Child
  • Adolescent
  • United States
Label
Hematopoietic stem-cell transplantation in the pediatric population, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center ; investigators, Thomas A. Ratko ... [et al.], (electronic resource)
Instantiates
Publication
Note
"February 2012."
Bibliography note
Includes bibliographical references
Dimensions
unknown
Extent
1 online resource (1 PDF file (various pagings))
Form of item
online
Other physical details
ill.
Specific material designation
remote
System control number
  • 1581820
  • (DNLM)BKSHLF:NBK84626
Label
Hematopoietic stem-cell transplantation in the pediatric population, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center ; investigators, Thomas A. Ratko ... [et al.], (electronic resource)
Publication
Note
"February 2012."
Bibliography note
Includes bibliographical references
Dimensions
unknown
Extent
1 online resource (1 PDF file (various pagings))
Form of item
online
Other physical details
ill.
Specific material designation
remote
System control number
  • 1581820
  • (DNLM)BKSHLF:NBK84626

Library Locations

  • African Studies LibraryBorrow it
    771 Commonwealth Avenue, 6th Floor, Boston, MA, 02215, US
    42.350723 -71.108227
  • Alumni Medical LibraryBorrow it
    72 East Concord Street, Boston, MA, 02118, US
    42.336388 -71.072393
  • Astronomy LibraryBorrow it
    725 Commonwealth Avenue, 6th Floor, Boston, MA, 02445, US
    42.350259 -71.105717
  • Fineman and Pappas Law LibrariesBorrow it
    765 Commonwealth Avenue, Boston, MA, 02215, US
    42.350979 -71.107023
  • Frederick S. Pardee Management LibraryBorrow it
    595 Commonwealth Avenue, Boston, MA, 02215, US
    42.349626 -71.099547
  • Howard Gotlieb Archival Research CenterBorrow it
    771 Commonwealth Avenue, 5th Floor, Boston, MA, 02215, US
    42.350723 -71.108227
  • Mugar Memorial LibraryBorrow it
    771 Commonwealth Avenue, Boston, MA, 02215, US
    42.350723 -71.108227
  • Music LibraryBorrow it
    771 Commonwealth Avenue, 2nd Floor, Boston, MA, 02215, US
    42.350723 -71.108227
  • Pikering Educational Resources LibraryBorrow it
    2 Silber Way, Boston, MA, 02215, US
    42.349804 -71.101425
  • School of Theology LibraryBorrow it
    745 Commonwealth Avenue, 2nd Floor, Boston, MA, 02215, US
    42.350494 -71.107235
  • Science & Engineering LibraryBorrow it
    38 Cummington Mall, Boston, MA, 02215, US
    42.348472 -71.102257
  • Stone Science LibraryBorrow it
    675 Commonwealth Avenue, Boston, MA, 02445, US
    42.350103 -71.103784
Processing Feedback ...